1. Home
  2. THCH vs SCLX Comparison

THCH vs SCLX Comparison

Compare THCH & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

N/A

Current Price

$2.09

Market Cap

58.9M

Sector

Finance

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$7.85

Market Cap

56.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
SCLX
Founded
2018
2011
Country
China
United States
Employees
N/A
34
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
56.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
THCH
SCLX
Price
$2.09
$7.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.9K
84.7K
Earning Date
04-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$4.09
52 Week High
$3.25
$34.27

Technical Indicators

Market Signals
Indicator
THCH
SCLX
Relative Strength Index (RSI) 43.50 47.72
Support Level $1.70 $7.73
Resistance Level $2.31 $8.18
Average True Range (ATR) 0.19 1.28
MACD -0.02 0.08
Stochastic Oscillator 33.87 20.88

Price Performance

Historical Comparison
THCH
SCLX

About THCH TH International Limited Ordinary shares

TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: